XML 96 R39.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Other operating expenses | 12 Months Ended
--- | ---
Dec. 31, 2024
Analysis of income and expense [abstract] |
Other operating expenses | Other operating expenses Other operating expenses totaled €4,382 million in 2024, compared with €3,443 million in 2023 and €2,523 million in 2022. Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. For 2024, this line item includes €3,955 million of expenses related to Regeneron (see Note C.1.), compared with €3,206 million for 2023 and €2,378 million for 2022 (as shown in the table below):
(€ million) | 2024 | 2023 | 2022
Income & expense related to sharing of (profits)/losses under the Monoclonal Antibody Alliance | (4,143) | (3,321) | (2,325)
Additional share of profit paid by Regeneron towards development costs(a) | 833 | 668 | 434
Reimbursement to Regeneron of selling expenses incurred | (637) | (543) | (476)
Total - Monoclonal Antibody Alliance | (3,947) | (3,196) | (2,367)
Immuno-Oncology Alliance | — | — | 16
Other (mainly Zaltrap and Libtayo) | 158 | 217 | 1,120
Other operating income/(expenses), net related to Regeneron | (3,789) | (2,979) | (1,231)
of which amount presented in Other operating income (Note D.25.) | 166 | 227 | 1,147
(a)As of December 31, 2024, the commitment received by Sanofi in respect of the additional profit share payable by Regeneron towards development costs amounted to €1.6 billion, compared with €2.1 billion as of December 31, 2023 (see Note D.21.). Charges to provisions for litigation and environmental risks are also recorded within this line item.

X
- References No definition available. + Details
Name: | ifrs-full_AnalysisOfIncomeAndExpenseAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of other operating expense. [Refer: Other operating income (expense)] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 10 -Subparagraph e -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_10_e&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration